InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.16
(
0.47%
)
US TECH 100
18,022.00
(
0.55%
)
Dow Jones
39,497.54
(
0.13%
)
Brent Oil
79.49
(
0.00%
)
Bitcoin
61,114.81
(
0.39%
)
Post# of 252817
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

drbio45

Send PM Follow Ignore
Followers 36
Posts 3185
Boards Moderated 0
Alias Born 10/18/2003

drbio45

Re: rkrw post# 93249

Friday, 03/26/2010 12:28:25 PM

Friday, March 26, 2010 12:28:25 PM

Post# of 252817
NEW YORK (AP) -- Canadian drug developer Biovail Corp. said Friday it bought several Ampakine compounds, aimed at treating a breathing disorder, for $9 million upfront, plus future payments.

Biovail said it bought the compounds from Cortex Pharmaceuticals Inc. They include CX717, now in midstage development.

Biovail will pay the upfront fee, along with an additional $1 million upon completion of a transition period. It could also pay up to $15 million in milestones.

this is clear
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up